

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M.7275 - NOVARTIS / GLAXOSMITHKLINE ONCOLOGY BUSINESS

SECTION 1.2

Description of the concentration

- (1) Novartis AG has entered into an agreement to acquire the business relating to a portfolio of oncology products (excluding manufacturing) from GlaxoSmithKline Plc (the “**GSK Oncology Business**”), which constitutes a concentration within the meaning of Article 3(1)(b) of Council Regulation (EC) N° 139/2004.
- (2) Novartis is a healthcare company headquartered in Basel (Switzerland), and listed on the SIX Swiss Exchange as well as on the New York Stock Exchange. Novartis is active in five broad areas of healthcare: pharmaceuticals, eye care, generics, Over-the-Counter (“**OTC**”) and vaccine products.
- (3) The GSK Oncology Business is active worldwide in the research, development, and marketing of oncology products for various indications.
- (4) The Proposed Transaction forms part of a three-part inter-conditional transaction whereby GSK has agreed to acquire sole control over Novartis’ vaccine business (excluding the influenza business) and GSK and Novartis have agreed to combine their consumer health businesses into a new venture under the sole control of GSK. These parts of the overall transaction constitute a separate concentration and have been notified as Case COMP/M.7276.